Wanglai Hu
Impact in
- Cancer Research top 2%
- MicroRNA in disease regulation
- Cancer-related molecular mechanisms research
- Cancer, Hypoxia, and Metabolism
- Molecular Biology top 10%
- Circular RNAs in diseases
- RNA modifications and cancer
- Epigenetics and DNA Methylation
Papers in
-
- RNA modifications and cancer 6
- Circular RNAs in diseases 5
- Ubiquitin and proteasome pathways 3
-
- Cancer-related molecular mechanisms research 6
- Cancer, Hypoxia, and Metabolism 5
- MicroRNA in disease regulation 4
- Co-authors
- Zhong‐Ping Feng (2 shared papers)Arnold J. Levine (2 shared papers)Mian Wu (9 shared papers)C. Zhang (1 shared paper)Rui Wu (1 shared paper)Rick F. Thorne (5 shared papers)Xu Dong Zhang (2 shared papers)Elke Markert (1 shared paper)
- Journals
- Oncotarget (3 papers)Journal of Cancer (2 papers)Biochemical Pharmacology (2 papers)Biomedicine & Pharmacotherapy (2 papers)Cell Death and Disease (2 papers)
- Partner nations
- ChinaUnited StatesAustralia
In The Last Decade
Wanglai Hu
42 papers receiving 1.7k citations
Peers
Comparison fields: 5 of 114
- Cancer Research 603
- Molecular Biology 1000
- Oncology 334
- Renewable Energy, Sustainability and the Environment 166
- Biotechnology 61
Countries citing papers authored by Wanglai Hu
This map shows the geographic impact of Wanglai Hu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wanglai Hu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wanglai Hu more than expected).
Fields of papers citing papers by Wanglai Hu
This network shows the impact of papers produced by Wanglai Hu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wanglai Hu. The network helps show where Wanglai Hu may publish in the future.
Co-authors
The 25 scholars most cited alongside Wanglai Hu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 42 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2019 | 255 | |
| 2 | 2009 | 217 | |
| 3 | 2011 | 189 | |
| 4 | 2020 | 165 | |
| 5 | 2012 | 125 | |
| 6 | 2020 | 101 | |
| 7 | 1993 | 72 | |
| 8 | 2013 | 58 | |
| 9 | 2015 | 46 | |
| 10 | 2019 | 45 | |
| 11 | 2019 | 43 | |
| 12 | 2016 | 37 | |
| 13 | 2019 | 36 | |
| 14 | 2022 | 29 | |
| 15 | KLF4 suppresses the migration of hepatocellular carcinoma by transcriptionally upregulating monoglyceride lipase. | 2018 | 28 |
| 16 | 2020 | 25 | |
| 17 | 2013 | 25 | |
| 18 | 2013 | 17 | |
| 19 | 2010 | 17 | |
| 20 | 2011 | 15 |
About Wanglai Hu
Wanglai Hu is a scholar working on Molecular Biology, Cancer Research, Oncology, Pathology and Forensic Medicine and Surgery, having authored 42 papers that have together received 1.7k indexed citations. Recurring topics across this work include Cancer-related molecular mechanisms research (6 papers), Cancer-related Molecular Pathways (6 papers), RNA modifications and cancer (6 papers), Circular RNAs in diseases (5 papers), Cancer, Hypoxia, and Metabolism (5 papers), MicroRNA in disease regulation (4 papers), Ubiquitin and proteasome pathways (3 papers) and Advanced Photocatalysis Techniques (2 papers). The work is most often cited by research in Cancer Research (603 citations), Molecular Biology (1000 citations), Oncology (334 citations), Renewable Energy, Sustainability and the Environment (166 citations) and Biotechnology (61 citations). Wanglai Hu has collaborated with scholars based in China, United States and Australia. Frequent co-authors include Zhong‐Ping Feng, Arnold J. Levine, Mian Wu, C. Zhang, Rui Wu, Rick F. Thorne, Xu Dong Zhang, Elke Markert, Anna M. Puzio‐Kuter and В. А. Белый. Their work appears in journals such as Oncotarget, Journal of Cancer, Biochemical Pharmacology, Biomedicine & Pharmacotherapy and Cell Death and Disease.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.